Russia Launches First Personalized Cancer Vaccine in Human Trials

Russia has taken a major step in cancer treatment by administering its first personalised vaccine to a patient. The groundbreaking therapy, designed to target individual tumours, marks a new phase in the country's healthcare strategy. Authorities have confirmed the treatment is now in clinical trials and will be fully state-funded for citizens. The vaccine was given to a 60-year-old man from Russia diagnosed with skin melanoma. He became the first participant in human trials after the treatment completed preclinical testing. Unlike standard therapies, this approach trains the immune system to identify and attack cancer cells specific to each patient.

Russia's Ministry of Health has emphasised the importance of personalised cancer treatments under its national healthcare plan. The government will cover all costs, ensuring free access for every citizen in need. Development of the vaccine has been closely monitored by state regulators as part of a broader push to advance precision medicine.

The trial represents a shift toward individualised cancer care in Russia. If successful, the vaccine could offer a targeted alternative to conventional treatments. Officials have not yet announced when the therapy might become widely available.